A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)

NCT ID: NCT01920633

Last Updated: 2017-07-19

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 135 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-10-31
• Study Completion Date: 2015-01-31

Brief Summary

This is a single visit study in which people with Down syndrome aged 12-30 will attend the clinical center to undergo assessments to evaluate their eligibility for potential enrollment in the future BP27832 Phase II clinical study which will evaluate the efficacy, safety and tolerability of RG1662. Study participants may withdraw from this study at any time and for any reason.

Conditions

Down Syndrome

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

People with Down syndrome

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

Study participants will be assessed on the following criteria that they will be required to meet in order to participate in the future Phase II study BP27832:

• Males and females 12-30 years of age (18-30 in the US)
• Clinical diagnosis of Down syndrome (trisomy 21) documented by chromosomal analysis (karyotyping)
• Body-mass Index (BMI) 18-42 and 15-32 kg/m2 inclusive for adults and adolescents respectively
• Ability to complete the Clinical Evaluation of Language Fundamentals (CELF)-preschool 2 word classes task (i.e., ≥ 7 for the adults or ≥ 4 for the adolescents in the expressive raw score).
• Study participant willing and assenting or consenting to participate
• Parent or guardian willing to give written informed consent
• Study participants must have a parent, or other reliable caregiver who will agree to accompany the study participant to clinic visits during the treatment study, BP27832
• The parent or caregiver must be a constant and reliable informant with sufficient contact with the study participant to have detailed knowledge of the study participant's adaptive functioning in order to be able to complete assessments accurately
• Study participants must be verbal and able to be understood most of the time and must not use other forms of communication, signs, symbol boards or devices as their primary form of communication
• Study participants must have sufficient vision and hearing to participate in study evaluations
• Study participants on anti-epileptic treatment must be on stable doses for 4 weeks prior to enrollment in the treatment protocol

Exclusion Criteria

In the future Phase II study, study participants must not meet any of the following criteria :

• Study participants with severe lactose intolerance
• Study participants with moderate or severe Obstructive Sleep Apnea (OSA) as defined by Apnea-Hypopnea Index (AHI) (>15 events per hour not well controlled by positive airway pressure therapy with stable settings) for 6 weeks prior to the screening visit
• Study participants with history of malignancy if not considered likely to be cured
• Personal history of infantile spasms, of epilepsy, of severe head trauma or Central Nervous System (CNS) infections (e.g. meningitis), with the exception of a single isolated febrile seizure
• Study participants with history of epilepsy within the last 2 years.
• Evidence of active, clinically significant, and unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease
• Study participants with a current Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of any primary psychiatric diagnosis (including autism spectrum disorder). Diagnoses that are secondary, such as intellectual disability, attention deficit hyperactivity disorder, depression and conduct disorder are allowed as long as they are considered stable and to not interfere with conduct of a future treatment study
• Study participants with a history of suicide attempt or deliberate self-harm due to suicidal ideation will not be included. Suicidal ideation (even in the absence of suicide attempt or deliberate self-harm) during the 6 months prior to screening
• Concomitant use of excluded approved or unapproved medications
• Personal or family history of congenital long QT syndrome
• History of hepatitis C or known Human Immunodeficiency Virus (HIV) infection
• Pregnant or breast feeding

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hoffmann-La Roche

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Univ of CA San Diego; Neurosciences Comp.Alzheimer's

La Jolla, California, United States

Emory University School of Medicine; Department of Human Genetics & Pediatrics

Decatur, Georgia, United States

Rush University Medical Center

Chicago, Illinois, United States

Johns Hopkins Hospital.

Baltimore, Maryland, United States

Massachusette General Hospital; Medical Genetics

Boston, Massachusetts, United States

Duke Clin Rsch Institute

Durham, North Carolina, United States

UT Southwestern Medical Center

Dallas, Texas, United States

University of Utah School of Medicine; Department of Pediatrics

Salt Lake City, Utah, United States

University of Wisconsin Madison, Waisman Center

Madison, Wisconsin, United States

Instituto de Investigaciones Neurologicas Raul Carrea FLENI

Capital Federal, , Argentina

Instituto Neurologia Bs As

Ciudad Autonoma de Bs As, , Argentina

True North Clinical Research Kentville

Kentville, Nova Scotia, Canada

Hospital Dr. Angel Leaño; Pediatria

Guadalajara, Jalisco, Mexico

Clínica Para la Atención del Neurodesarrollo

Aguascalientes, , Mexico

Hospital Médica Tec 100

Querétaro, , Mexico

Auckland Clinical Studies

Auckland, , New Zealand

University of Otago; Psychological Medicine Department

Dunedin, , New Zealand

Wellington Hospital Research Office

Wellington, , New Zealand

KK Women's and Children's Hospital; Department of Neonatology

Singapore, , Singapore

UVaMID Hospital Santa Caterina;; Servicio de Neurología

Salt, Girona, Spain

IMIM, Human Pharmacology and Clinical Neurosciences,

Barcelona, , Spain

Hospital Universitario de la Princesa; Medicina Interna

Madrid, , Spain

Countries

United States; Argentina; Canada; Mexico; New Zealand; Singapore; Spain

Other Identifiers

2013-001264-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BP28947

Identifier Type: -

Identifier Source: org_study_id